MedinCell S.A. (MEDCL.PA)
EUR 15.48
(1.84%)
EUR 15.48
(1.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 77.77 Million EUR | 8.57% |
| 2022 | 71.63 Million EUR | 24.2% |
| 2021 | 57.67 Million EUR | 5.95% |
| 2020 | 54.43 Million EUR | 26.06% |
| 2019 | 43.18 Million EUR | 36.05% |
| 2018 | 31.73 Million EUR | -14.45% |
| 2017 | 37.1 Million EUR | 45.2% |
| 2016 | 25.55 Million EUR | 159.47% |
| 2015 | 9.84 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 76.23 Million EUR | 0.0% |
| 2023 Q4 | 77.77 Million EUR | 0.0% |
| 2023 FY | 77.77 Million EUR | 8.57% |
| 2022 FY | 71.63 Million EUR | 24.2% |
| 2022 Q4 | 71.63 Million EUR | 0.0% |
| 2022 Q2 | 58.84 Million EUR | 0.0% |
| 2021 FY | 57.67 Million EUR | 5.95% |
| 2021 Q2 | 56.42 Million EUR | 0.0% |
| 2021 Q4 | 57.67 Million EUR | 0.0% |
| 2020 Q2 | 53.09 Million EUR | 0.0% |
| 2020 Q4 | 54.64 Million EUR | 0.0% |
| 2020 FY | 54.43 Million EUR | 26.06% |
| 2019 FY | 43.18 Million EUR | 36.05% |
| 2019 Q2 | 37.26 Million EUR | 0.0% |
| 2019 Q4 | 43.18 Million EUR | 0.0% |
| 2018 Q4 | 31.73 Million EUR | 0.0% |
| 2018 FY | 31.73 Million EUR | -14.45% |
| 2018 Q3 | 31.73 Million EUR | -33.66% |
| 2018 Q2 | 47.84 Million EUR | 0.0% |
| 2018 Q1 | 47.84 Million EUR | 28.96% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q3 | 37.1 Million EUR | 0.0% |
| 2017 Q4 | 37.1 Million EUR | 0.0% |
| 2017 FY | 37.1 Million EUR | 45.2% |
| 2016 FY | 25.55 Million EUR | 159.47% |
| 2015 FY | 9.84 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -1025.145% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 40.657% |
| Adocia SA | 31.87 Million EUR | -144.023% |
| Aelis Farma SA | 13.08 Million EUR | -494.572% |
| Biophytis S.A. | 15.84 Million EUR | -390.693% |
| Advicenne S.A. | 24.37 Million EUR | -219.03% |
| genOway Société anonyme | 14.45 Million EUR | -437.847% |
| IntegraGen SA | 5.97 Million EUR | -1200.546% |
| Medesis Pharma S.A. | 6.42 Million EUR | -1110.205% |
| Neovacs S.A. | 3.71 Million EUR | -1995.027% |
| NFL Biosciences SA | 3.62 Million EUR | -2047.937% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -1046.652% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -2249.471% |
| Sensorion SA | 13.22 Million EUR | -487.952% |
| Theranexus Société Anonyme | 5.01 Million EUR | -1450.38% |
| TME Pharma N.V. | 2.78 Million EUR | -2692.46% |
| Valbiotis SA | 13.7 Million EUR | -467.333% |
| TheraVet SA | 1.48 Million EUR | -5137.062% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -279.959% |
| DBV Technologies S.A. | 38.74 Million USD | -100.721% |
| Genfit S.A. | 105.92 Million EUR | 26.577% |
| GeNeuro SA | 20.13 Million EUR | -286.149% |
| Innate Pharma S.A. | 132.29 Million EUR | 41.213% |
| Inventiva S.A. | 101.59 Million EUR | 23.449% |
| MaaT Pharma SA | 22.46 Million EUR | -246.183% |
| Nanobiotix S.A. | 95.74 Million EUR | 18.77% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -31.637% |
| Poxel S.A. | 53.9 Million EUR | -44.283% |
| GenSight Biologics S.A. | 34.72 Million EUR | -123.947% |
| Transgene SA | 26.51 Million EUR | -193.284% |
| Valneva SE | 341.14 Million EUR | 77.203% |